Literature DB >> 6163579

Evaluation of alternative pathway and factor B haemolytic activities in patients with systemic lupus erythematosus: correlations with the alternative pathway regulatory proteins.

M T Aguado, L H Perrin, R Ramirez, P A Miescher, P H Lambert.   

Abstract

The haemolytic activities of the complement alternative pathway and factor B were studied using a 51Cr-release assay in 77 sera from patients with systemic lupus erythematosus (SLE). These values were compared to those of several complement components and of the regulatory proteins beta H and C3b INA. There was a significant decrease in the alternative pathway activity, which correlated with a decrease in the haemolytic activity of factor B and with the activity of the classical pathway. There was a significant decrease in the level of one regulatory protein beta 1H, while the level of the other regulatory protein, C3b INA, was increased; however, there was a positive correlation between these two parameters. The results obtained suggest that the decreased activity of the alternative pathway observed in SLE reflects a consumption due to a triggering of the C3b amplification loop through the activation of the classical pathway. In one patient, an acquired deficiency of the capacity to activate the alternative pathway in the presence of inulin was observed.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6163579      PMCID: PMC1537163     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  28 in total

1.  The quantitation of alternative pathway complement function by timed lysis assay.

Authors:  B M Jones
Journal:  J Immunol Methods       Date:  1979       Impact factor: 2.303

2.  Relationships between the haemolytic activities of the human complement system and complement components.

Authors:  A Takada; Y Imamura; Y Takada
Journal:  Clin Exp Immunol       Date:  1979-02       Impact factor: 4.330

3.  Variable patterns of immunoglobulin and complement deposition in the kidneys of patients with systemic lupus erythematosus.

Authors:  D Koffler; V Agnello; R I Carr; H G Kunkel
Journal:  Am J Pathol       Date:  1969-09       Impact factor: 4.307

4.  Decreased properdin activity in acute glomerulonephritis.

Authors:  H Gewurz; R J Pickering; G Naff; R Snyderman; S E Mergenhagen; R A Good
Journal:  Int Arch Allergy Appl Immunol       Date:  1969

5.  The modulation of the alternative pathway of complement in C2-deficient human serum by changes in concentration of the component and control proteins.

Authors:  U E Nydegger; D T Fearon; K F Austen
Journal:  J Immunol       Date:  1978-04       Impact factor: 5.422

6.  Kinetic assessment of alternative complement pathway activity in a hemolytic system. I. Experimental and mathematical analyses.

Authors:  R B Polhill; K M Pruitt; R B Johnston
Journal:  J Immunol       Date:  1978-07       Impact factor: 5.422

7.  Studies of the C3 shunt activation in cobra venom induced lysis of unsensitized erythrocytes.

Authors:  M Brai; A G Osler
Journal:  Proc Soc Exp Biol Med       Date:  1972-07

8.  Relative importance of C3b inactivator and beta 1H globulin in the modulation of the properdin amplification loop in systemic lupus erythematosus.

Authors:  K Whaley; P H Schur; S Ruddy
Journal:  Clin Exp Immunol       Date:  1979-06       Impact factor: 4.330

9.  Metabolism of human beta 1H: studies in man and experimental animals.

Authors:  J A Charlesworth; D M Scott; B A Pussell; D K Peters
Journal:  Clin Exp Immunol       Date:  1979-12       Impact factor: 4.330

10.  Requirements for beta1H globulin and C3b inactivator in the control of the alternative complement pathway in human serum.

Authors:  K Whaley; R A Thompson
Journal:  Immunology       Date:  1978-12       Impact factor: 7.397

View more
  5 in total

1.  Partial H (beta 1H) deficiency and glomerulonephritis in two families.

Authors:  R J Wyatt; B A Julian; A Weinstein; N F Rothfield; R H McLean
Journal:  J Clin Immunol       Date:  1982-04       Impact factor: 8.317

2.  Reversal of immune complex inhibition of antibody-dependent cell-mediated cytotoxicity by normal human serum.

Authors:  M A Isturiz; S B Fink; M M de Bracco
Journal:  Clin Exp Immunol       Date:  1982-06       Impact factor: 4.330

3.  Development and application of an enzyme-linked immunosorbent assay for the quantitation of alternative complement pathway activation in human serum.

Authors:  J T Mayes; R D Schreiber; N R Cooper
Journal:  J Clin Invest       Date:  1984-01       Impact factor: 14.808

4.  A circulating inhibitor of fluid-phase amplification. C3 convertase formation in systemic lupus erythematosus.

Authors:  F B Waldo; J Forristal; L Beischel; C D West
Journal:  J Clin Invest       Date:  1985-06       Impact factor: 14.808

5.  Reduced complement-mediated immune complex solubilizing capacity and the presence of incompletely solubilized immune complexes in SLE sera.

Authors:  G Baatrup; I Petersen; J C Jensenius; S E Svehag
Journal:  Clin Exp Immunol       Date:  1983-11       Impact factor: 4.330

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.